The regional pharmacovigilance centres inform the Agence nationale de sécurité du médicament et des produits de santé on the same day of the reports of adverse reactions likely to be due to a blood-derived medicinal product that they have received.
Home | French Legislation Articles | Part five: Health products | Book I: Pharmaceutical products | Title II: Medicinal products for human use | Chapter I: General provisions | Section 13: Pharmacovigilance | Subsection 5: Blood-derived medicinal products | Paragraph 3: Reporting obligations. | Article R5121-198 of the French Public Health Code
The regional pharmacovigilance centres inform the Agence nationale de sécurité du médicament et des produits de santé on the same day of the reports of adverse reactions likely to be due to a blood-derived medicinal product that they have received.
Les centres régionaux de pharmacovigilance informent le jour même l’Agence nationale de sécurité du médicament et des produits de santé des déclarations d’effets indésirables susceptibles d’être dus à un médicament dérivé du sang qu’ils ont reçues.
Our French business lawyers are here to help.
We offer a FREE evaluation of your case.
Call us at +33 (0) 1 84 88 31 00 or send us an email.
is a Registered Trademark of
PETROFF LAW FIRM (SELARL LEGASTRAT)
182, rue de Rivoli
75001, Paris France
RCS Paris n°814433470
Paris Bar Registration n° (Toque) C2396
is a Registered Trademark of
PETROFF LAW FIRM (SELARL LEGASTRAT)
182, rue de Rivoli
75001, Paris France
RCS Paris n°814433470
Paris Bar Registration n° (Toque) C2396
Resources
is a Registered Trademark of
PETROFF LAW FIRM (SELARL LEGASTRAT)
182, rue de Rivoli
75001, Paris France
RCS Paris n°814433470
Paris Bar Registration n° (Toque) C2396
Useful links
Our French business lawyers are here to help.
We offer a FREE evaluation of your case.
Call +33 (0) 1 84 88 31 00 or send us an email.
All information exchanged through this website will be communicated to lawyers registered with a French Bar and will remain confidential.